脂質低下薬市場(薬物クラス:スタチン&コンビネーション、PCSK9阻害剤、胆汁酸封鎖剤、フィブラート、コレステロール吸収阻害剤、その他) - 世界各国の産業分析、サイズ、シェア、成長、トレンド、予測、2023-2031年Lipid-lowering Drugs Market (Drug Class: Statins & Combination, PCSK9 Inhibitors, Bile Acid Sequestrants, Fibrates, Cholesterol Absorption Inhibitors, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031 脂質低下薬市場 - レポートの範囲 TMRの調査レポート「世界の脂質低下薬市場」は、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向や機会も調... もっと見る
サマリー脂質低下薬市場 - レポートの範囲TMRの調査レポート「世界の脂質低下薬市場」は、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向や機会も調査しています。本レポートでは、2023年を基準年、2031年を予測年として、2017年から2031年までの期間における世界の脂質低下薬市場の収益を提供します。また、2023年から2031年までの脂質低下薬の世界市場の複合年間成長率(CAGR %)を掲載しています。 本レポートは、広範な調査を経て作成されました。一次調査では、主要なオピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、脂質低下薬市場を把握しました。 また、インターネット上の情報源、政府機関の統計データ、ウェブサイト、業界団体なども二次調査の対象とした。アナリストは、トップダウンアプローチとボトムアップアプローチを組み合わせて、世界の脂質低下薬市場の様々な属性を調査しました。 本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、本レポートは、世界の脂質低下薬市場における競争ダイナミクスの変化に光を当てています。これらは、既存の市場関係者だけでなく、世界の脂質低下薬市場への参入を検討している企業にとっても、貴重なツールとなります。 本レポートは、世界の脂質低下薬市場の競争環境について掘り下げています。世界の脂質低下薬市場で事業を展開する主要企業が特定され、それぞれの企業が様々な属性でプロファイリングされています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界の脂質低下薬市場のプレーヤーの属性です。 脂質低下薬の世界市場レポートで回答された主な質問 - 予測期間中、全地域における脂質低下薬の売上/収益はどの程度か? - 世界の脂質低下薬市場におけるビジネスチャンスは何か? - 市場における主な促進要因、阻害要因、機会、脅威は何か? - 予測期間中に最も速いCAGRで拡大する地域市場はどこか? - 2031年に世界で最も高い収益を上げると予測されるセグメントは? - 予測期間中に最も高いCAGRで拡大すると予測されるセグメントはどこか? - 世界市場で事業展開している各社の市場ポジションは? 脂質低下薬市場 - 研究目的と研究アプローチ 脂質低下薬の世界市場に関する包括的なレポートは、まず概要から始まり、次に調査範囲と目的について説明しています。本調査の目的、市場で活動する主要ベンダーや流通業者、製品の承認に関する規制シナリオについて詳しく解説しています。 読みやすさを考慮し、本レポートは章立てでまとめられ、各セクションはより小さなものに分割されています。本レポートは、グラフと表が適切に配置された包括的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴えかけています。また、過去と予測期間終了時の主要セグメントの市場シェアを比較することも可能です。 本レポートでは、脂質低下薬の世界市場を製品、エンドユーザー、地域の観点から分析しています。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントごとの市場シェアを掲載しています。このような貴重な洞察により、市場関係者は、世界の脂質低下薬市場への投資について、情報に基づいたビジネス上の意思決定を行うことができます。 目次1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Lipid-lowering Drugs Market 4. Market Overview 4.1. Introduction 4.1.1. Segment Definition 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Lipid-lowering Drugs Market Analysis and Forecast, 2017-2031 4.4.1. Market Revenue Projections (US$ Mn) 5. Key Insights 5.1. Drug Pipeline Analysis 5.2. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact) 5.3. Regulatory Scenario by Region/globally 5.4. Patent Analysis 6. Global Lipid-lowering Drugs Market Analysis and Forecast, by Drug Class 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Market Value Forecast, by Drug Class, 2017-2031 6.3.1. Statins & Combination 6.3.2. PCSK9 Inhibitors 6.3.3. Bile Acid Sequestrants 6.3.4. Fibrates 6.3.5. Cholesterol Absorption Inhibitors 6.3.6. Others 6.4. Market Attractiveness, by Drug Class 7. Global Lipid-lowering Drugs Market Analysis and Forecast, by Indication 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Market Value Forecast, by Indication, 2017-2031 7.3.1. Hypercholesterolemia 7.3.2. Coronary Artery Disease 7.3.3. High Triglycerides 7.4. Market Attractiveness, by Indication 8. Global Lipid-lowering Drugs Market Analysis and Forecast, by Distribution Channel 8.1. Introduction & Definition 8.2. Key Findings / Developments 8.3. Market Value Forecast, by Distribution Channel, 2017-2031 8.3.1. Hospital Pharmacies 8.3.2. Retail Pharmacies 8.3.3. Online Pharmacies 8.4. Market Attractiveness, by Distribution Channel 9. Global Lipid-lowering Drugs Market Analysis and Forecast, by Region 9.1. Key Findings 9.2. Market Value Forecast, by Region 9.2.1. North America 9.2.2. Europe 9.2.3. Asia Pacific 9.2.4. Latin America 9.2.5. Middle East & Africa 9.3. Market Attractiveness, by Country/Region 10. North America Lipid-lowering Drugs Market Analysis and Forecast 10.1. Introduction 10.1.1. Key Findings 10.2. Market Value Forecast, by Drug Class, 2017-2031 10.2.1. Statins & Combination 10.2.2. PCSK9 Inhibitors 10.2.3. Bile Acid Sequestrants 10.2.4. Fibrates 10.2.5. Cholesterol Absorption Inhibitors 10.2.6. Others 10.3. Market Value Forecast, by Indication, 2017-2031 10.3.1. Hypercholesterolemia 10.3.2. Coronary Artery Disease 10.3.3. High Triglycerides 10.4. Market Value Forecast, by Distribution Channel, 2017-2031 10.4.1. Hospital Pharmacies 10.4.2. Retail Pharmacies 10.4.3. Online Pharmacies 10.5. Market Value Forecast, by Country, 2017-2031 10.5.1. U.S. 10.5.2. Canada 10.6. Market Attractiveness Analysis 10.6.1. By Drug Class 10.6.2. By Indication 10.6.3. By Distribution Channel 10.6.4. By Country 11. Europe Lipid-lowering Drugs Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Drug Class, 2017-2031 11.2.1. Statins & Combination 11.2.2. PCSK9 Inhibitors 11.2.3. Bile Acid Sequestrants 11.2.4. Fibrates 11.2.5. Cholesterol Absorption Inhibitors 11.2.6. Others 11.3. Market Value Forecast, by Indication, 2017-2031 11.3.1. Hypercholesterolemia 11.3.2. Coronary Artery Disease 11.3.3. High Triglycerides 11.4. Market Value Forecast, by Distribution Channel, 2017-2031 11.4.1. Hospital Pharmacies 11.4.2. Retail Pharmacies 11.4.3. Online Pharmacies 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031 11.5.1. Germany 11.5.2. U.K. 11.5.3. France 11.5.4. Spain 11.5.5. Italy 11.5.6. Rest of Europe 11.6. Market Attractiveness Analysis 11.6.1. By Drug Class 11.6.2. By Indication 11.6.3. By Distribution Channel 11.6.4. By Country/Sub-region 12. Asia Pacific Lipid-lowering Drugs Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by Drug Class, 2017-2031 12.2.1. Statins & Combination 12.2.2. PCSK9 Inhibitors 12.2.3. Bile Acid Sequestrants 12.2.4. Fibrates 12.2.5. Cholesterol Absorption Inhibitors 12.2.6. Others 12.3. Market Value Forecast, by Indication, 2017-2031 12.3.1. Hypercholesterolemia 12.3.2. Coronary Artery Disease 12.3.3. High Triglycerides 12.4. Market Value Forecast, by Distribution Channel, 2017-2031 12.4.1. Hospital Pharmacies 12.4.2. Retail Pharmacies 12.4.3. Online Pharmacies 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031 12.5.1. China 12.5.2. Japan 12.5.3. India 12.5.4. Australia & New Zealand 12.5.5. Rest of Asia Pacific 12.6. Market Attractiveness Analysis 12.6.1. By Drug Class 12.6.2. By Indication 12.6.3. By Distribution Channel 12.6.4. By Country/Sub-region 13. Latin America Lipid-lowering Drugs Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Drug Class, 2017-2031 13.2.1. Statins & Combination 13.2.2. PCSK9 Inhibitors 13.2.3. Bile Acid Sequestrants 13.2.4. Fibrates 13.2.5. Cholesterol Absorption Inhibitors 13.2.6. Others 13.3. Market Value Forecast, by Indication, 2017-2031 13.3.1. Hypercholesterolemia 13.3.2. Coronary Artery Disease 13.3.3. High Triglycerides 13.4. Market Value Forecast, by Distribution Channel, 2017-2031 13.4.1. Hospital Pharmacies 13.4.2. Retail Pharmacies 13.4.3. Online Pharmacies 13.5. Market Value Forecast By Country/Sub-region, 2017-2031 13.5.1. Brazil 13.5.2. Mexico 13.5.3. Rest of Latin America 13.6. Market Attractiveness Analysis 13.6.1. By Drug Class 13.6.2. By Indication 13.6.3. By Distribution Channel 13.6.4. By Country/Sub-region 14. Middle East & Africa Lipid-lowering Drugs Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Drug Class, 2017-2031 14.2.1. Statins & Combination 14.2.2. PCSK9 Inhibitors 14.2.3. Bile Acid Sequestrants 14.2.4. Fibrates 14.2.5. Cholesterol Absorption Inhibitors 14.2.6. Others 14.3. Market Value Forecast, by Indication, 2017-2031 14.3.1. Hypercholesterolemia 14.3.2. Coronary Artery Disease 14.3.3. High Triglycerides 14.4. Market Value Forecast, by Distribution Channel, 2017-2031 14.4.1. Hospital Pharmacies 14.4.2. Retail Pharmacies 14.4.3. Online Pharmacies 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031 14.5.1. GCC Countries 14.5.2. South Africa 14.5.3. Rest of Middle East & Africa 14.6. Market Attractiveness Analysis 14.6.1. By Drug Class 14.6.2. By Indication 14.6.3. By Distribution Channel 14.6.4. By Country/Sub-region 15. Competition Landscape 15.1. Market Player – Competition Matrix (By Tier and Size of companies) 15.2. Market Share/Ranking Analysis By Company (2022) 15.3. Company Profiles 15.3.1. Sanofi 15.3.1.1. Company Overview 15.3.1.2. Product Portfolio 15.3.1.3. SWOT Analysis 15.3.1.4. Strategic Overview 15.3.2. Pfizer, Inc. 15.3.2.1. Company Overview 15.3.2.2. Product Portfolio 15.3.2.3. SWOT Analysis 15.3.2.4. Strategic Overview 15.3.3. GlaxoSmithKline plc 15.3.3.1. Company Overview 15.3.3.2. Product Portfolio 15.3.3.3. SWOT Analysis 15.3.3.4. Strategic Overview 15.3.4. Novartis AG 15.3.4.1. Company Overview 15.3.4.2. Product Portfolio 15.3.4.3. SWOT Analysis 15.3.4.4. Strategic Overview 15.3.5. Merck & Co., Inc. 15.3.5.1. Company Overview 15.3.5.2. Product Portfolio 15.3.5.3. SWOT Analysis 15.3.5.4. Strategic Overview 15.3.6. Amgen Inc. 15.3.6.1. Company Overview 15.3.6.2. Product Portfolio 15.3.6.3. SWOT Analysis 15.3.6.4. Strategic Overview 15.3.7. Takeda Pharmaceutical Company Limited 15.3.7.1. Company Overview 15.3.7.2. Product Portfolio 15.3.7.3. SWOT Analysis 15.3.7.4. Strategic Overview 15.3.8. Sun Pharmaceutical Industries Ltd. 15.3.8.1. Company Overview 15.3.8.2. Product Portfolio 15.3.8.3. SWOT Analysis 15.3.8.4. Strategic Overview 15.3.9. AbbVie, Inc. 15.3.9.1. Company Overview 15.3.9.2. Product Portfolio 15.3.9.3. SWOT Analysis 15.3.9.4. Strategic Overview 15.3.10. Viatris (Mylan N.V.) 15.3.10.1. Company Overview 15.3.10.2. Product Portfolio 15.3.10.3. SWOT Analysis 15.3.10.4. Strategic Overview 15.3.11. AstraZeneca PLC 15.3.11.1. Company Overview 15.3.11.2. Product Portfolio 15.3.11.3. SWOT Analysis 15.3.11.4. Strategic Overview 15.3.12. Dr. Reddy’s Laboratories Ltd. 15.3.12.1. Company Overview 15.3.12.2. Product Portfolio 15.3.12.3. SWOT Analysis 15.3.12.4. Strategic Overview 図表リストList of TablesTable 01: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031 Table 02: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by 2017‒2031, by Indication Table 03: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 04: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031 Table 05: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031 Table 06: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031 Table 07: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031 Table 08: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 09: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031 Table 10: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031 Table 11: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031 Table 12: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 13: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031 Table 14: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031 Table 15: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031 Table 16: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 17: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031 Table 18: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031 Table 19: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031 Table 20: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 21: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031 Table 22: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031 Table 23: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031 Table 24: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
SummaryLipid-lowering Drugs Market – Scope of Report Table of Contents1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Lipid-lowering Drugs Market 4. Market Overview 4.1. Introduction 4.1.1. Segment Definition 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Lipid-lowering Drugs Market Analysis and Forecast, 2017-2031 4.4.1. Market Revenue Projections (US$ Mn) 5. Key Insights 5.1. Drug Pipeline Analysis 5.2. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact) 5.3. Regulatory Scenario by Region/globally 5.4. Patent Analysis 6. Global Lipid-lowering Drugs Market Analysis and Forecast, by Drug Class 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Market Value Forecast, by Drug Class, 2017-2031 6.3.1. Statins & Combination 6.3.2. PCSK9 Inhibitors 6.3.3. Bile Acid Sequestrants 6.3.4. Fibrates 6.3.5. Cholesterol Absorption Inhibitors 6.3.6. Others 6.4. Market Attractiveness, by Drug Class 7. Global Lipid-lowering Drugs Market Analysis and Forecast, by Indication 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Market Value Forecast, by Indication, 2017-2031 7.3.1. Hypercholesterolemia 7.3.2. Coronary Artery Disease 7.3.3. High Triglycerides 7.4. Market Attractiveness, by Indication 8. Global Lipid-lowering Drugs Market Analysis and Forecast, by Distribution Channel 8.1. Introduction & Definition 8.2. Key Findings / Developments 8.3. Market Value Forecast, by Distribution Channel, 2017-2031 8.3.1. Hospital Pharmacies 8.3.2. Retail Pharmacies 8.3.3. Online Pharmacies 8.4. Market Attractiveness, by Distribution Channel 9. Global Lipid-lowering Drugs Market Analysis and Forecast, by Region 9.1. Key Findings 9.2. Market Value Forecast, by Region 9.2.1. North America 9.2.2. Europe 9.2.3. Asia Pacific 9.2.4. Latin America 9.2.5. Middle East & Africa 9.3. Market Attractiveness, by Country/Region 10. North America Lipid-lowering Drugs Market Analysis and Forecast 10.1. Introduction 10.1.1. Key Findings 10.2. Market Value Forecast, by Drug Class, 2017-2031 10.2.1. Statins & Combination 10.2.2. PCSK9 Inhibitors 10.2.3. Bile Acid Sequestrants 10.2.4. Fibrates 10.2.5. Cholesterol Absorption Inhibitors 10.2.6. Others 10.3. Market Value Forecast, by Indication, 2017-2031 10.3.1. Hypercholesterolemia 10.3.2. Coronary Artery Disease 10.3.3. High Triglycerides 10.4. Market Value Forecast, by Distribution Channel, 2017-2031 10.4.1. Hospital Pharmacies 10.4.2. Retail Pharmacies 10.4.3. Online Pharmacies 10.5. Market Value Forecast, by Country, 2017-2031 10.5.1. U.S. 10.5.2. Canada 10.6. Market Attractiveness Analysis 10.6.1. By Drug Class 10.6.2. By Indication 10.6.3. By Distribution Channel 10.6.4. By Country 11. Europe Lipid-lowering Drugs Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Drug Class, 2017-2031 11.2.1. Statins & Combination 11.2.2. PCSK9 Inhibitors 11.2.3. Bile Acid Sequestrants 11.2.4. Fibrates 11.2.5. Cholesterol Absorption Inhibitors 11.2.6. Others 11.3. Market Value Forecast, by Indication, 2017-2031 11.3.1. Hypercholesterolemia 11.3.2. Coronary Artery Disease 11.3.3. High Triglycerides 11.4. Market Value Forecast, by Distribution Channel, 2017-2031 11.4.1. Hospital Pharmacies 11.4.2. Retail Pharmacies 11.4.3. Online Pharmacies 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031 11.5.1. Germany 11.5.2. U.K. 11.5.3. France 11.5.4. Spain 11.5.5. Italy 11.5.6. Rest of Europe 11.6. Market Attractiveness Analysis 11.6.1. By Drug Class 11.6.2. By Indication 11.6.3. By Distribution Channel 11.6.4. By Country/Sub-region 12. Asia Pacific Lipid-lowering Drugs Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by Drug Class, 2017-2031 12.2.1. Statins & Combination 12.2.2. PCSK9 Inhibitors 12.2.3. Bile Acid Sequestrants 12.2.4. Fibrates 12.2.5. Cholesterol Absorption Inhibitors 12.2.6. Others 12.3. Market Value Forecast, by Indication, 2017-2031 12.3.1. Hypercholesterolemia 12.3.2. Coronary Artery Disease 12.3.3. High Triglycerides 12.4. Market Value Forecast, by Distribution Channel, 2017-2031 12.4.1. Hospital Pharmacies 12.4.2. Retail Pharmacies 12.4.3. Online Pharmacies 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031 12.5.1. China 12.5.2. Japan 12.5.3. India 12.5.4. Australia & New Zealand 12.5.5. Rest of Asia Pacific 12.6. Market Attractiveness Analysis 12.6.1. By Drug Class 12.6.2. By Indication 12.6.3. By Distribution Channel 12.6.4. By Country/Sub-region 13. Latin America Lipid-lowering Drugs Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Drug Class, 2017-2031 13.2.1. Statins & Combination 13.2.2. PCSK9 Inhibitors 13.2.3. Bile Acid Sequestrants 13.2.4. Fibrates 13.2.5. Cholesterol Absorption Inhibitors 13.2.6. Others 13.3. Market Value Forecast, by Indication, 2017-2031 13.3.1. Hypercholesterolemia 13.3.2. Coronary Artery Disease 13.3.3. High Triglycerides 13.4. Market Value Forecast, by Distribution Channel, 2017-2031 13.4.1. Hospital Pharmacies 13.4.2. Retail Pharmacies 13.4.3. Online Pharmacies 13.5. Market Value Forecast By Country/Sub-region, 2017-2031 13.5.1. Brazil 13.5.2. Mexico 13.5.3. Rest of Latin America 13.6. Market Attractiveness Analysis 13.6.1. By Drug Class 13.6.2. By Indication 13.6.3. By Distribution Channel 13.6.4. By Country/Sub-region 14. Middle East & Africa Lipid-lowering Drugs Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Drug Class, 2017-2031 14.2.1. Statins & Combination 14.2.2. PCSK9 Inhibitors 14.2.3. Bile Acid Sequestrants 14.2.4. Fibrates 14.2.5. Cholesterol Absorption Inhibitors 14.2.6. Others 14.3. Market Value Forecast, by Indication, 2017-2031 14.3.1. Hypercholesterolemia 14.3.2. Coronary Artery Disease 14.3.3. High Triglycerides 14.4. Market Value Forecast, by Distribution Channel, 2017-2031 14.4.1. Hospital Pharmacies 14.4.2. Retail Pharmacies 14.4.3. Online Pharmacies 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031 14.5.1. GCC Countries 14.5.2. South Africa 14.5.3. Rest of Middle East & Africa 14.6. Market Attractiveness Analysis 14.6.1. By Drug Class 14.6.2. By Indication 14.6.3. By Distribution Channel 14.6.4. By Country/Sub-region 15. Competition Landscape 15.1. Market Player – Competition Matrix (By Tier and Size of companies) 15.2. Market Share/Ranking Analysis By Company (2022) 15.3. Company Profiles 15.3.1. Sanofi 15.3.1.1. Company Overview 15.3.1.2. Product Portfolio 15.3.1.3. SWOT Analysis 15.3.1.4. Strategic Overview 15.3.2. Pfizer, Inc. 15.3.2.1. Company Overview 15.3.2.2. Product Portfolio 15.3.2.3. SWOT Analysis 15.3.2.4. Strategic Overview 15.3.3. GlaxoSmithKline plc 15.3.3.1. Company Overview 15.3.3.2. Product Portfolio 15.3.3.3. SWOT Analysis 15.3.3.4. Strategic Overview 15.3.4. Novartis AG 15.3.4.1. Company Overview 15.3.4.2. Product Portfolio 15.3.4.3. SWOT Analysis 15.3.4.4. Strategic Overview 15.3.5. Merck & Co., Inc. 15.3.5.1. Company Overview 15.3.5.2. Product Portfolio 15.3.5.3. SWOT Analysis 15.3.5.4. Strategic Overview 15.3.6. Amgen Inc. 15.3.6.1. Company Overview 15.3.6.2. Product Portfolio 15.3.6.3. SWOT Analysis 15.3.6.4. Strategic Overview 15.3.7. Takeda Pharmaceutical Company Limited 15.3.7.1. Company Overview 15.3.7.2. Product Portfolio 15.3.7.3. SWOT Analysis 15.3.7.4. Strategic Overview 15.3.8. Sun Pharmaceutical Industries Ltd. 15.3.8.1. Company Overview 15.3.8.2. Product Portfolio 15.3.8.3. SWOT Analysis 15.3.8.4. Strategic Overview 15.3.9. AbbVie, Inc. 15.3.9.1. Company Overview 15.3.9.2. Product Portfolio 15.3.9.3. SWOT Analysis 15.3.9.4. Strategic Overview 15.3.10. Viatris (Mylan N.V.) 15.3.10.1. Company Overview 15.3.10.2. Product Portfolio 15.3.10.3. SWOT Analysis 15.3.10.4. Strategic Overview 15.3.11. AstraZeneca PLC 15.3.11.1. Company Overview 15.3.11.2. Product Portfolio 15.3.11.3. SWOT Analysis 15.3.11.4. Strategic Overview 15.3.12. Dr. Reddy’s Laboratories Ltd. 15.3.12.1. Company Overview 15.3.12.2. Product Portfolio 15.3.12.3. SWOT Analysis 15.3.12.4. Strategic Overview List of Tables/GraphsList of TablesTable 01: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031 Table 02: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by 2017‒2031, by Indication Table 03: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 04: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031 Table 05: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031 Table 06: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031 Table 07: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031 Table 08: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 09: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031 Table 10: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031 Table 11: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031 Table 12: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 13: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031 Table 14: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031 Table 15: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031 Table 16: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 17: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031 Table 18: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031 Table 19: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031 Table 20: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 21: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031 Table 22: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031 Table 23: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031 Table 24: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(その他)の最新刊レポート
Transparency Market Research 社の最新刊レポート
本レポートと同じKEY WORD(analysis size)の最新刊レポート
よくあるご質問Transparency Market Research社はどのような調査会社ですか?トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/05 10:26 153.43 円 167.28 円 201.52 円 |